Q-omics provides the consensus-scored RPL29P30 profile across patient tissues and cancer cell-line models. RPL29P30 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL29P30 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, RPL29P30 RNA expression shows 8,802 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, LIHC, and TGCT as cancer lineages where RPL29P30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL29P30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL29P30 survival associations across molecular data types. RPL29P30 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL29P30 RNA expression–survival associations across cancer types. High RPL29P30 expression shows unfavorable associations in ACC, BLCA, PAAD and CHOL, but favorable associations in LUSC and GBM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL29P30 RNA expression.
This table summarizes RPL29P30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL29P30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL29P30 shows lower tumor expression in BRCA, READ and HNSC and higher tumor expression in LIHC, BLCA and PRAD. The LIHC box plot shows higher RPL29P30 RNA expression in tumor versus normal tissue (log2 FC = +0.068, t-test p = .001).
This table shows molecular features associated with RPL29P30 in patient tissues and cancer cell lines. In patient samples, RPL29P30 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
